We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) (OPTIRPE65)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02781480
Recruitment Status : Recruiting
First Posted : May 24, 2016
Last Update Posted : December 18, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
A clinical trial of AAV2/5 vector for patients with Defects in RPE65

Condition or disease Intervention/treatment Phase
Leber Congenital Amaurosis Biological: AAV RPE65 Phase 1 Phase 2

Detailed Description:
A dose escalation and dose expansion (Phase I/II) trial of adults and children with retinal dystrophy associated with defects in RPE65. ATIMP will be administered to one eye only in a single sub-retinal procedure

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: AAV2/5-OPTIRPE65
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)
Study Start Date : April 2016
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : October 2018


Arms and Interventions

Arm Intervention/treatment
Experimental: Low dose AAV-RPE65
Subretinal administration of a single low dose of range AAV-RPE65
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65
Experimental: Intermediate dose AAV-RPE65
Subretinal administration of a single intermediate dose of range AAV-RPE65
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65
Experimental: High dose AAV-RPE65
Subretinal administration of a single high dose of range AAV-RPE65
Biological: AAV RPE65
Comparison of different dosages of AAV RPE65


Outcome Measures

Primary Outcome Measures :
  1. Incidence of Adverse Events related to the treatment [ Time Frame: 1 year ]
    Safety is defined as the absence of ATIMP-related safety events


Secondary Outcome Measures :
  1. Improvement in visual function [ Time Frame: 6 months ]
    Improvements in visual function as assessed by visual assessment

  2. Improvement in retinal function [ Time Frame: 6 months ]
    Improvements in retinal function as assessed by visual assessment

  3. Improvement in Quality of Life [ Time Frame: 6 months ]
    Quality of life will be measured by QoL questionnaire


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Aged 3 years or older
  • Early-onset severe retinal dystrophy consistent with RPE65 deficiency

Key Exclusion Criteria:

  • Females who are pregnant or breastfeeding
  • Have participated in another research study involving an investigational therapy for ocular disease within the last 6 months.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781480


Contacts
Contact: Julie Bakobaki julie.bakobaki@meiragtx.com
Contact: Praseeda Thaikalloor praseeda.thaikalloor@meiragtx.com

Locations
United Kingdom
Moorfields Eye Hospital NHS Foundation Trust Recruiting
London, United Kingdom, EC1V 2PD
Contact: James Bainbridge       j.bainbridge@ucl.ac.uk   
Contact: Michel Michaelides       michel.michaelides@ucl.ac.uk   
Principal Investigator: James Bainbridge, Prof         
Sub-Investigator: Michel Michaelides, Prof         
Sponsors and Collaborators
MeiraGTx UK II Ltd
More Information

Responsible Party: MeiraGTx UK II Ltd
ClinicalTrials.gov Identifier: NCT02781480     History of Changes
Other Study ID Numbers: MGT003
First Posted: May 24, 2016    Key Record Dates
Last Update Posted: December 18, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Blindness
Leber Congenital Amaurosis
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms
Eye Diseases, Hereditary
Retinal Diseases